FDA approves manufacturing site for Definity

| | Health Imaging | Cardiac Imaging

The FDA has approved Jubilant HollisterStier (JHS) as a manufacturing site for Lantheus Medical Imaging’s ultrasound imaging agent Definity Vial for Injectable Suspension.

Definity is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

Currently, Definity is manufactured by Ben Venue Laboratories in Bedford, Ohio. In August 2011, Ben Venue announced that it will exit the contract manufacturing services business over the next several years. In February 2012, North Billerica, Mass.-based Lantheus entered into a manufacturing and supply agreement with JHS for the manufacture of Definity. 

Lantheus entered into similar agreements with JHS in May 2012 for the manufacture and supply of Cardiolite and Neurolite, which are also currently manufactured by Ben Venue.

JHS will become the lead supplier of Definity, as well as Cardiolite and Neurolite, as Ben Venue transitions out of the contract manufacturing services business, Lantheus said in a press release.

Related Content

Global shortage of nuclear imaging isotopes may be over
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
FDA clears AI tool that flags signs of heart disease in chest CT scans
AI-enabled plaque assessments help cardiologists ID high-risk CAD patients
Abbott CGM sensors can now be worn during common imaging procedures
New data highlight long-term benefits of HeartFlow’s AI-based CAD evaluations

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup